Overview

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Sofosbuvir